| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
(2R/S)-6-PNG targets the Cav3.2 T-type calcium channel (T-channel). It acts as a blocker, inhibiting calcium influx through these channels. Additionally, it has been identified as a histone deacetylase (HDAC) inhibitor, suggesting a dual mechanism of action involving ion channel modulation and epigenetic regulation. The compound can cross the blood-brain barrier, making it relevant for central nervous system applications.
|
|---|---|
| ln Vitro |
In differentiated NG108-15 cells, (2R/S)-6-PNG (6-Prenylnaringenin) does not significantly affect voltage-gated Na+ channels or high-voltage-activated Ca2+ channels [1]. However, it can effectively block Cav3.2. The inhibitory potency of (2R/S)-6-PNG on Cav3.2 and HVA currents has an IC50 value of 5.20; consequently, the ratio of Cav3.2 and Nav currents is 3.54 (Cav3.2/Nav)[1].
In vitro, (2R/S)-6-PNG is a potent and reversible blocker of Cav3.2 T-type calcium channels. As an HDAC inhibitor, it exhibits anticancer and antitumor activity. The compound's ability to inhibit T-type calcium channels is responsible for its analgesic effects in neuropathic and visceral pain models. Specific IC50 values for channel blockade are not provided in the available sources. |
| ln Vivo |
(2R/S)-6-PNG (6-prenylnaringenin; 10-30 mg/kg; i.p.; single dose; 15 min before Na2S) greatly lowers Na2S-induced intracolonic Nociceptive behavior and/or related hyperalgesia (i.col.) Administration of Na2S (an H2S donor) [1]. (2R/S)-6-PNG (30 mg/kg; i.p.) reduced the rise in the number of phosphorylated ERK-positive cells following i.col. Primary afferent neurons project to Na2S in layers I-II, V-VI and X, and Na2S generates an increase in the number of phosphorylated ERK-positive cells [1]. (2R/S)-6-PNG (0.01-1 and 0.1-10 nmol/paw; intraplantar injection) reversed mechanical damage caused by partial sciatic nerve ligation (PSNL) and intraperitoneal treatment of oxaliplatin (OHP)a, respectively Allodynia is dose-dependent [1]. (2R/S)-6-PNG (20-30 mg/kg; i.p.) effectively corrected PSNL-induced allodynia. (2R/S)-6-PNG (10-20 mg/kg; i.p.) effectively reverses OHP-induced allodynia (5 mg/kg; i.p.; single dose) [1].
In vivo, (2R/S)-6-PNG suppresses neuropathic and visceral pain in mice. It can penetrate the blood-brain barrier, suggesting central nervous system activity. The compound is administered intraperitoneally (i.p.) in animal studies, though specific doses and regimens are not detailed in the available sources. Its analgesic effects are attributed to T-type calcium channel blockade. |
| Enzyme Assay |
The in vitro enzyme/receptor binding assay for (2R/S)-6-PNG typically involves measuring its inhibition of Cav3.2 T-type calcium channels using electrophysiological techniques such as patch-clamp recordings. Alternatively, calcium influx assays using fluorescent indicators (e.g., Fluo-4) can be employed to assess channel activity in cells expressing Cav3.2 channels. The compound's binding affinity and inhibition kinetics are determined from dose-response curves.
|
| Cell Assay |
Cellular assays are performed using cell lines expressing Cav3.2 T-type calcium channels. Cells are treated with varying concentrations of (2R/S)-6-PNG, and calcium influx is measured using fluorescent calcium indicators or electrophysiological methods. The compound's potency as a channel blocker is assessed by calculating IC50 values from inhibition curves.
|
| Animal Protocol |
In vivo animal studies involve administration of (2R/S)-6-PNG to mice via intraperitoneal (i.p.) injection. The compound's ability to suppress neuropathic and visceral pain is evaluated using established pain models, such as the formalin test or von Frey filament test. Brain penetration is assessed by measuring compound concentrations in brain tissue.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of (2R/S)-6-PNG include its ability to penetrate the blood-brain barrier (BBB). This property is crucial for its central nervous system effects. The compound is soluble in DMSO and can be formulated for in vivo administration. Specific PK parameters such as half-life, bioavailability, and clearance are not detailed in the available sources.
|
| Toxicity/Toxicokinetics |
Toxicity data for (2R/S)-6-PNG are not reported in the available sources. As a natural product-derived compound, it is generally considered to have a favorable safety profile, but specific toxicological studies are not described. The compound is used for research purposes only and is not intended for therapeutic use.
|
| References | |
| Additional Infomation |
(S)-4',5,7-Trihydroxy-6-isopentenylflavanone is a type of flavanone compound. (S)-4',5,7-Trihydroxy-6-isopentenylflavanone has been found in plants of the genus Psoralea and Sophora japonica, and relevant data have been reported.
(2R/S)-6-PNG is a research compound with potential applications in pain management and cancer therapy. Its dual activity as a T-type calcium channel blocker and HDAC inhibitor makes it an interesting tool for studying these pathways. The compound is available from chemical suppliers for research use only. |
| Molecular Formula |
C20H20O5
|
|---|---|
| Molecular Weight |
340.3698
|
| Exact Mass |
340.131
|
| CAS # |
68682-01-9
|
| Related CAS # |
(2S)-6-Prenylnaringenin;68236-13-5
|
| PubChem CID |
3519901
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
209 - 209.5 °C
|
| LogP |
4.3
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
25
|
| Complexity |
504
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O1C2C([H])=C(C(C([H])([H])/C(/[H])=C(\C([H])([H])[H])/C([H])([H])[H])=C(C=2C(C([H])([H])C1([H])C1C([H])=C([H])C(=C([H])C=1[H])O[H])=O)O[H])O[H]
|
| InChi Key |
YHWNASRGLKJRJJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H20O5/c1-11(2)3-8-14-15(22)9-18-19(20(14)24)16(23)10-17(25-18)12-4-6-13(21)7-5-12/h3-7,9,17,21-22,24H,8,10H2,1-2H3
|
| Chemical Name |
5,7-dihydroxy-2-(4-hydroxyphenyl)-6-(3-methylbut-2-enyl)-2,3-dihydrochromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~367.25 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.11 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (6.11 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (6.11 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9380 mL | 14.6899 mL | 29.3798 mL | |
| 5 mM | 0.5876 mL | 2.9380 mL | 5.8760 mL | |
| 10 mM | 0.2938 mL | 1.4690 mL | 2.9380 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
